Drug/Small Molecule:
peginterferon alfa-2b

last updated 10/04/2013

CPIC Dosing Guideline for boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, telaprevir and IFNL3

Summary

IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients. Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.

Annotation

Guidelines regarding the use of pharmacogenomic tests in PEG-interferon-alpha (PEG-IFN alpha) and ribavirin (RBV) therapy have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC).

Download: accepted article preview and supplement

Excerpt from the PEG-interferon-alpha-containing regimens guidelines:

The role of IFNL3 genotyping depends on treatment selection. IFNL3 genotype is only one factor that could influence response rates to PEG-IFN alpha and RBV therapy in HCV genotype 1 infection and should be interpreted in the context of other clinical and genetic factors.

For patients treated with PEG-IFN alpha and RBV alone, IFNL3 genotype is the strongest pretreatment predictor of HCV treatment response. In the intention to treat analysis of the original discovery cohort with rs12979860, Caucasian CC genotype patients were more likely than CT or TT patients to be undetectable by week 4 (28% versus 5% and 5%, P<0.0001) and to achieve SVR (69% versus 33% and 27%, P<0.0001). Similar patterns were observed in Hispanic and African American patients in this cohort. HCV treatment is associated with significant side effects, and the likelihood of response treatment influences shared decision making between clinicians and patients about initiating treatment.

For treatment naïve patients with genotype 1 infection who are treated with protease inhibitor combinations, all IFNL3 genotypes have improved response rates compared to PEG-IFN alpha and RBV only. However, patients with the favorable IFNL3 genotype still have higher response rates with the protease inhibitor combination in treatment naïve patients, and these response rates may guide patients and clinicians in their treatment decisions. In the boceprevir phase 3 naïve study of combination with PEG-IFN alpha and RBV, SVR rates for rs12979860 CC patients receiving boceprevir ranged from 80-82% compared to 65-71% for CT patients and 59-65% for TT patients. Moreover, multivariate regression analysis revealed that rs12979860 CC was a predictor of SVR compared to CT (odds ratio (OR) 2.6, 95% CI 1.3-5.1) and TT genotypes (OR 2.1, 95% CI 1.2-3.7).

Recommendations for use of PEG-interferon-alpha-containing regimens based on IFNL3 genotype (Table 2):
Genotype at rs12979860 Phenotype Implications for PEG-IFN alpha and RBV a Implications for protease inhibitor combinations with PEG-IFN alpha and RBV therapy Classification of recommendations b
CC Favorable response genotype Approximately 70% chance for SVR c after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Approximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks)d. Weighs in favor of using PEG-IFN alpha and RBV containing regimens. Strong
CT or TT Unfavorable response genotype Approximately 30% chance for SVR c after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks)d. Consider implications before initiating PEG-IFN and RBV containing regimens. Strong

a In cases where a protease inhibitor is not available.
b Rating scheme described in Supplement.
c SVR; sustained virologic response (defined by undetectable serum viral RNA 12-24 weeks after the end of treatment).
d Patients receiving boceprevir are eligible for 24-28 weeks instead of the standard 48 weeks if HCV RNA is undetectable by week eight. Patients receiving telaprevir are eligible for 24 weeks of therapy instead of the standard 48 weeks if HCV RNA is undetectable by week four.

PEG-IFN alpha: pegylated-interferon alpha 2a or 2b; RBV: ribavirin


PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.


last updated 10/25/2013

FDA Label for peginterferon alfa-2b and IFNL3

This label is on the FDA Biomarker List
Actionable PGx

Summary

Pegylated recombinant human interferon alfa-2b is an inducer of the innate antiviral immune response. A single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B rs12979860) was associated with variable sustained viral response (SVR) rates. SVR rates by rs12979860 genotype were as follows: CC 66% vs. CT 30% vs. TT 22%.

Annotation

PegIntron, peginterferon alfa-2b, is a covalent conjugate of recombinant alfa-2b interferon for the treatment of chronic hepatitis C infection. Pegylated recombinant human interferon alfa-2b is an inducer of the innate antiviral immune response. Peginterferon alfa-2b binds to and activates the human type 1 interferon receptor.

Excerpt from the PegIntron (Peginterferon alfa-2b) drug label:

When administering PegIntron with medications metabolized by CYP2C8/9 (e.g., warfarin and phenytoin) or CYP2D6 (e.g.,
flecainide), the therapeutic effect of these substrates may be decreased.

A retrospective genome-wide association analysis1,2 of 1,671 subjects (1,604 subjects from Study 4 and 67 subjects from another clinical trial) was performed to identify human genetic contributions to anti-HCV treatment response in previously untreated HCV genotype 1 subjects. A single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B rs12979860) was associated with variable SVR rates. The rs12979860 genotype was categorized as CC, CT and TT. In the pooled analysis of Caucasian, African-American, and Hispanic subjects from these trials (n=1,587), SVR rates by rs12979860 genotype were as follows: CC 66% vs. CT 30% vs. TT 22%. The genotype frequencies differed depending on racial/ethnic background, but the relationship of SVR to IL28B genotype was consistent across various racial/ethnic groups (see Table 12). Other variants near the IL28B gene (e.g., rs8099917 and rs8103142) have been identified; however, they have not been shown to independently influence SVR rates during treatment with pegylated interferon alpha therapies combined with ribavirin"

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the PegIntron (Peginterferon alfa-2b) drug label PDF.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Hepatitis
    • Indications & usage section, Contraindications section, Warnings section, Adverse reactions section
    • source: PHONT
  • Hepatitis C
    • Warnings section, Adverse reactions section
    • source: PHONT
  • Hepatitis C, Chronic
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • IFNL3
    • Clinical pharmacology section, efficacy
    • source: FDA Label

European Medicines Agency (EMA) Label for peginterferon alfa-2b

Summary

No human pharmacogenetic information could be found in the EMA European Public Assessment Report (EPAR) for peginterferon alfa-2b (PegIntron): 25th July 2013.

Annotation

The peginterferon alfa-2b (PegIntron) EMA EPAR contains information regarding the indication of the drug in patients with chronic hepatitis C (CHC) genotype 1 infection.

Read the peginterferon alfa-2b (PegIntron) EMA drug label

*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.


Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
Quest Diagnostics AccuType® IL28B test rs12979860
LabCorp Interleukin 28B (IL28B) Polymorphism (rs12979860) test rs12979860
ARUP's Lab IL28B-Associated Variants Test rs12979860 , rs8099917

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available No VIP available VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1127354 194C>A, 194C>G, 194C>T, 286C>A, 286C>G, 286C>T, 3133842C>A, 3133842C>G, 3133842C>T, 3193842C>A, 3193842C>G, 3193842C>T, 43C>A, 43C>G, 43C>T, 49-62C>A, 49-62C>G, 49-62C>T, 67-789C>A, 67-789C>G, 67-789C>T, 8787C>A, 8787C>G, 8787C>T, 94C>A, 94C>G, 94C>T, ITPA, ITPA: 94C>A, P32T, Pro15Ala, Pro15Ser, Pro15Thr, Pro32Ala, Pro32Ser, Pro32Thr
C > G
C > T
C > A
Not Available
Pro15Thr
No VIP available CA VA
rs12819210 *499G>A, 1119G>A, 12034930C>T, 121458400C>T, 1509G>A, Ser373=, Ser503=
C > T
Synonymous
Ser373Ser
No VIP available CA VA
rs12979860 12007005C>T, 39738787C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs12980275 12000001A>G, 39731783A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs1800795 -237C>G, 22756645C>G, 22766645C>G, 4880C>G, 50-321G>C
C > G
Intronic
No VIP available No Clinical Annotations available VA
rs187238 -368G>C, 112034988C>G, 15597404C>G, 4853G>C
C > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs1946518 -838A>C, 112035458T>G, 15597874T>G, 4383A>C
T > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs231775 204732714A>G, 49A>G, 5206A>G, 54942132A>G, CTLA4:A49G, Thr17Ala
A > G
Missense
Thr17Ala
No VIP available No Clinical Annotations available VA
rs2660 *84G>A, 113357442G>A, 1189G>A, 17704G>A, 3933972G>A, Gly397Arg
G > A
Missense
Gly397Arg
No VIP available No Clinical Annotations available VA
rs28416813 -37G>C, 12003862C>G, 39735644C>G
C > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs304478 -1548G>T, -1645G>T, -1750G>T, -1755G>T, -1876G>T, 41955386G>T, 91150922G>T
G > T
5' Flanking
No VIP available CA VA
rs368234815
TT > G
Not Available
No VIP available No Clinical Annotations available VA
rs4969170 41634690A>G, 621T>C, 76360538A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs7270101 124+21A>C, 224+21A>C, 3133893A>C, 316+21A>C, 3193893A>C, 49-11A>C, 67-738A>C, 73+21A>C, 8838A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs760370 1260-201A>G, 44140953A>G, 44200953A>G
A > G
Intronic
No VIP available CA VA
rs8099917 12011383T>G, 39743165T>G
T > G
Not Available
No VIP available CA VA
rs8103142 12003324T>C, 209A>G, 39735106T>C, Lys70Arg
T > C
Missense
Lys70Arg
No VIP available CA VA
rs9657182 27623994C>T, 39765848C>T
C > T
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Generic Names
Trade Names
  • PEG-Intron (Schering Corp)
  • PEG-Intron (Schering Corp)
  • Unitron PEG
Brand Mixture Names

PharmGKB Accession Id:
PA164784024

Description

Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of Escherichia coli bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.

Source: Drug Bank

Indication

For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.

Source: Drug Bank

Pharmacology

Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Absorption

Following a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t½ k a) was 4.6 hours.

Source: Drug Bank

Half-Life

The mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

Renal elimination accounts for 30% of the clearance.

Source: Drug Bank

Chemical Properties

Canonical SMILES

Not Available

Source: Drug Bank

Average Molecular Weight

31000.0000

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
IFNAR1 (source: Drug Bank)
IFNAR2 (source: Drug Bank)

Drug Interactions

Drug Description
aminophylline Interferon increases the effect and toxicity of theophylline (source: Drug Bank)
dyphylline Interferon increases the effect and toxicity of theophylline (source: Drug Bank)
oxtriphylline Interferon increases the effect and toxicity of theophylline (source: Drug Bank)
theophylline Interferon increases the effect and toxicity of theophylline (source: Drug Bank)

Curated Information ?

Publications related to peginterferon alfa-2b: 53

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IFNL4 polymorphism affects on outcome of telaprevir, peg-interferon and ribavirin combination therapy for chronic hepatitis C. Hepatology research : the official journal of the Japan Society of Hepatology. 2014. Nagaoki Yuko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Alimentary pharmacology & therapeutics. 2014. Covolo L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS (London, England). 2014. Franco Sandra, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. Journal of gastroenterology and hepatology. 2014. Tsubota Akihito, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphism in IFNL4 and response to pegylated interferon-alpha and ribavirin in Japanese chronic hepatitis C patients. Tissue antigens. 2014. Nozawa Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. Journal of gastroenterology. 2013. Fujino Hatsue, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. Journal of hepatology. 2013. Pol Stanislas, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. Journal of viral hepatitis. 2013. Piluso A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism. Journal of viral hepatitis. 2013. Stenkvist J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature genetics. 2013. Prokunina-Olsson Ludmila, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Gene. 2013. Luo Yueqiu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012. Poordad Fred, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients. Journal of viral hepatitis. 2012. Riva E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes. Pharmacogenomics. 2012. Lagging Martin. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. Journal of gastroenterology. 2012. Kobayashi Mariko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of hepatology. 2012. Asselah Tarik, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut. 2012. Antaki Nabil, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants. PloS one. 2012. Vidal Francesc, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic Variants of Interferon-Stimulated Genes and IL-28B as Host Prognostic Factors of Response to Combination Treatment for Chronic Hepatitis C. Clinical pharmacology and therapeutics. 2011. Lopez-Rodriguez R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver international : official journal of the International Association for the Study of the Liver. 2011. Hayashi Kazuhiko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. Journal of medical virology. 2011. Toyoda Hidenori, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. Alimentary pharmacology & therapeutics. 2011. Giannini E G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. The Journal of infectious diseases. 2011. Chayama Kazuaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. Journal of medical virology. 2011. Hashimoto Yoshimasa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-alpha-induced depression in patients with chronic hepatitis C. Molecular psychiatry. 2011. Smith A K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. The Journal of infectious diseases. 2011. Lindh Magnus, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS (London, England). 2011. Rallón Norma I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. Journal of clinical microbiology. 2011. Ito Kiyoaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. Journal of hepatology. 2011. Scherzer Thomas-Matthias, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. Journal of medical virology. 2011. Sakamoto Naoya, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology (Baltimore, Md.). 2011. Moghaddam Amir, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. Journal of hepatology. 2011. Kawaoka Tomokazu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proceedings of the National Academy of Sciences of the United States of America. 2011. Hsu Ching-Sheng, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut. 2011. Hayes C Nelson, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology (Baltimore, Md.). 2011. Suzuki Fumitaka, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology (Baltimore, Md.). 2011. Thompson Alexander J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. Journal of acquired immune deficiency syndromes (1999). 2011. de Araujo Evaldo Stanislau Affonso, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (Baltimore, Md.). 2011. Darling Jama M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology (Baltimore, Md.). 2011. Yu Ming-Lung, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antiviral therapy. 2011. Liao Xiang-Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (Baltimore, Md.). 2010. Urban Thomas J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PloS one. 2011. Lagging Martin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010. Medrano Jose, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010. Pineda Juan A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. The Journal of infectious diseases. 2010. Morello Judit, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010. McCarthy Jeanette J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS (London, England). 2010. Rallón Norma I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Molecular psychiatry. 2009. Bull S J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PloS one. 2010. Aparicio Ester, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature genetics. 2009. Tanaka Yasuhito, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response. Journal of clinical immunology. 2009. Haas Stephan L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009. Ge Dongliang, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
UniProtKB:
IFNA2_HUMAN (P01563)
National Drug Code Directory:
0085-1323-01
DrugBank:
DB00022
Drugs Product Database (DPD):
2242966
Therapeutic Targets Database:
DAP001279
FDA Drug Label at DailyMed:
0a8f3137-0e3a-4a60-a872-cb7d761b30e1

Clinical Trials

These are trials that mention peginterferon alfa-2b and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.